RxDoctor Payments Data

Jane Gilmore, MD

Ophthalmology · Dallas, TXNPI 1104386564

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 23 payments — averaging $87.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$715
  • Glaukos Corporation$393
  • Bausch & Lomb Americas Inc.$359
  • Tarsus Pharmaceuticals, Inc.$160
  • Sight Sciences, Inc.$153
  • AbbVie$117
  • plus $109 from 4 others

What the payments were for

  • Food & beverage$2,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,005 in reported general payments places this provider in the 50th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$16,242
Medicare patients
152
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$15,785
VyzultaLatanoprostene Bunod20$13,757
RhopressaNetarsudil Mesylate25$12,633
LumiganBimatoprost28$12,247
CombiganBrimonidine Tartrate/Timolol22$9,770
Prednisolone Acetate179$9,361
RocklatanNetarsudil Mesylat/Latanoprost13$8,499
Methazolamide29$8,296
Brimonidine Tartrate174$7,729
Brinzolamide27$4,801
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol34$4,198
Latanoprost390$3,927
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat179$3,704
SimbrinzaBrinzolamide/Brimonidine Tart12$3,355
MoxifloxacinMoxifloxacin Hcl153$3,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$117$37,80274 claims
Bausch & Lomb Americas Inc.Vyzulta$359$13,75720 claims
AlconSimbrinza$715$3,35512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →